OncomiR-10b hijacks the small molecule inhibitor linifanib in human cancers

The pervasive role of microRNAs (miRNAs) in cancer pathobiology drives the introduction of new drug development approaches such as miRNA inhibition. In order to advance miRNA-therapeutics, meticulous screening strategies addressing specific tumor targets are needed. Small molecule inhibitors represe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Scientific reports 2018-08, Vol.8 (1), p.13106-13, Article 13106
Hauptverfasser: Monroig-Bosque, Paloma del C., Shah, Maitri Y., Fu, Xiao, Fuentes-Mattei, Enrique, Ling, Hui, Ivan, Cristina, Nouraee, Nazila, Huang, Beibei, Chen, Lu, Pileczki, Valentina, Redis, Roxana S., Jung, Eun-Jung, Zhang, Xinna, Lehrer, Michael, Nagvekar, Rahul, Mafra, Ana Carolina P., Monroig-Bosque, Maria del Mar, Irimie, Alexandra, Rivera, Carlos, Dan Dumitru, Calin, Berindan-Neagoe, Ioana, Nikonowicz, Edward P., Zhang, Shuxing, Calin, George A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The pervasive role of microRNAs (miRNAs) in cancer pathobiology drives the introduction of new drug development approaches such as miRNA inhibition. In order to advance miRNA-therapeutics, meticulous screening strategies addressing specific tumor targets are needed. Small molecule inhibitors represent an attractive goal for these strategies. In this study, we devised a strategy to screen for small molecule inhibitors that specifically inhibit, directly or indirectly, miR-10b (SMIRs) which is overexpressed in metastatic tumors. We found that the multi-tyrosine kinase inhibitor linifanib could significantly inhibit miR-10b and reverse its oncogenic function in breast cancer and liver cancer both in vitro and in vivo . In addition, we showed that the efficacy of linifanib to inhibit tyrosine kinases was reduced by high miR-10b levels. When the level of miR-10b is high, it can “hijack” the linifanib and reduce its kinase inhibitory effects in cancer resulting in reduced anti-tumor efficacy. In conclusion, our study describes an effective strategy to screen for small molecule inhibitors of miRNAs. We further propose that miR-10b expression levels, due to the newly described “hijacking” effect, may be used as a biomarker to select patients for linifanib treatment.
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-018-30989-3